# PRIMAVERA (NCT06137144)

> AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06137144
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Peripheral T-cell Lymphoma (PTCL); PTCL-NOS; ALCL; AITL
- Interventions: AZD3470; Pembrolizumab
- Enrollment: 161
- Primary outcome: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Primary outcome: Incidence of DLTs (Dose Escalation Cohorts only)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=primavera-nct06137144